Michelle Kenyon
Michelle Kenyon is an associate research fellow in Drug Safety at Pfizer Research and Development in Groton, CT where she has worked since 1993. She received her undergraduate degree in Biology from Quinnipiac University in New Haven, CT and her graduate degree in Biology (MA) from Brown University in Providence, RI.
Michelle has more than 25 years of experience in the application of genetic toxicology testing in support of pharmaceutical development, with expertise in screening and regulatory bacterial mutagenicity assays and the use of in silico tools to assess the mutagenic potential of pharmaceutical intermediates and impurities. She represents Drug Safety on a multidisciplinary council that provides advice to teams regarding impurity qualification matters and contributes to the development of risk assessments to address potential safety issues that arise across Pfizer’s global marketed product supplies. She is involved in IQ DruSafe and EFPIA workgroups addressing qualification of pharmaceutical impurities, as well as industry nitrosamine collaborations. Michelle is a long-time member of the Genetic Toxicology Association and is a past chair of the board of directors.
